Thus, B-cell targeting therapies, such as rituximab, that deplete FcRL4+ B cells and restore of the ductal epithelium may be beneficial in patients with pSS and even prevent MALT lymphoma development within the salivary glands. Here, FCRL4 is linked to MALT lymphoma.